Incyte Corporation

Incyte Corporation, based in Wilmington, Delaware, is a globally recognized biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics to address serious unmet medical needs, primarily in oncology, hematology, and dermatology. Founded in 2002 by a team of highly experienced research scientists, Incyte has built a world-class medicinal chemistry engine, excelling at designing highly targeted small-molecule inhibitors.

The company achieved massive success and revolutionized the treatment of myeloproliferative neoplasms (rare blood cancers like myelofibrosis and polycythemia vera) with the development of Jakafi, a pioneering Janus kinase (JAK) inhibitor. Building on this profound understanding of the JAK-STAT biological pathway, Incyte strategically expanded its portfolio into dermatology, launching Opzelura, a topical formulation for the treatment of atopic dermatitis and vitiligo.

Beyond JAK inhibitors, Incyte is aggressively advancing a diverse, robust clinical pipeline that includes targeted therapies and immunotherapies, such as FGFR inhibitors and monoclonal antibodies for various solid tumors and hematologic malignancies. The company operates a sprawling, state-of-the-art research headquarters in Delaware, alongside European operations based in Switzerland.

Incyte is known for its highly collaborative business model, maintaining lucrative strategic partnerships and co-development agreements with global pharmaceutical giants like Novartis and Eli Lilly, which maximize the global reach of their internally discovered molecules. Driven by a rigorous, science-first approach, Incyte continues to deliver highly effective, specialized medicines to patients worldwide.